MCID: VRR004
MIFTS: 54

Verrucous Carcinoma

Categories: Cancer diseases, Oral diseases

Aliases & Classifications for Verrucous Carcinoma

MalaCards integrated aliases for Verrucous Carcinoma:

Name: Verrucous Carcinoma 12 15 17
Verrucous Squamous Cell Carcinoma 12
Verrucous Squamous Carcinoma 12
Carcinoma, Verrucous 45
Carcinoma Verrucous 56
Warty Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3737
MeSH 45 D018289
NCIt 51 C3781
SNOMED-CT 69 89906000
UMLS 74 C0206706

Summaries for Verrucous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that is a diffuse, papillary, non metastasizing, well differentiated, malignant neoplasm of epidermis or oral epithelium.

MalaCards based summary : Verrucous Carcinoma, also known as verrucous squamous cell carcinoma, is related to papilloma and vulva cancer. An important gene associated with Verrucous Carcinoma is MSN (Moesin), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Fluorouracil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include skin, cervix and brain, and related phenotypes are Decreased viability with paclitaxel and cellular

Wikipedia : 77 Verrucous carcinoma (VC) is an uncommon variant of squamous cell carcinoma. This form of cancer is... more...

Related Diseases for Verrucous Carcinoma

Diseases related to Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 papilloma 30.4 CCND1 CDKN2A KRT10 TP53
2 vulva cancer 30.3 CDKN2A TP53
3 vulva squamous cell carcinoma 30.3 CDKN2A TP53
4 scrotal carcinoma 30.3 CDKN2A TP53
5 oral leukoplakia 30.2 CCND1 CDKN2A TP53
6 inverted papilloma 30.2 CCND1 CDKN2A TP53
7 oral cancer 30.2 CCND1 CDKN2A TP53
8 squamous cell papilloma 30.1 CDKN2A TP53
9 squamous cell carcinoma, head and neck 29.7 CCND1 CDKN2A TP53
10 keratoacanthoma 29.6 KRT10 TP53
11 larynx verrucous carcinoma 12.4
12 esophagus verrucous carcinoma 12.4
13 supraglottis verrucous carcinoma 12.3
14 cervical verrucous carcinoma 12.3
15 vulva verrucous carcinoma 12.3
16 glottis verrucous carcinoma 12.2
17 subglottis verrucous carcinoma 12.2
18 urethral verrucous carcinoma 12.1
19 penis non-invasive verrucous carcinoma 12.1
20 penis verrucous carcinoma 12.1
21 buschke lowenstein tumor 11.5
22 anal buschke-lowenstein tumor 11.5
23 proliferative verrucous leukoplakia 11.2
24 bladder verrucous squamous cell carcinoma 11.1
25 squamous cell carcinoma 10.6
26 penile cancer, adult 10.4
27 oral squamous cell carcinoma 10.4
28 bladder squamous cell carcinoma 10.4 CDKN2A TP53
29 ring chromosome 7 10.4 MDM2 TP53
30 zika virus infection 10.4 MDM2 TP53
31 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
32 spitz nevus 10.4 CDKN2A TP53
33 bladder carcinoma in situ 10.4 CDKN2A TP53
34 actinic cheilitis 10.4 MDM2 TP53
35 cheilitis 10.4 MDM2 TP53
36 thyroid lymphoma 10.4 CDKN2A TP53
37 vulvar disease 10.4 CDKN2A TP53
38 nasal cavity adenocarcinoma 10.4 CDKN2A TP53
39 sclerosing liposarcoma 10.4 MDM2 TP53
40 bartholin's gland disease 10.4 CDKN2A TP53
41 lip cancer 10.4 MDM2 TP53
42 anal squamous cell carcinoma 10.4 CDKN2A TP53
43 infiltrating angiolipoma 10.4 CDKN2A MDM2
44 megaesophagus 10.4 CDKN2A TP53
45 glycogen-rich clear cell breast carcinoma 10.4 CDKN2A TP53
46 breast papillomatosis 10.4 CCND1 CDKN2A
47 gastric adenosquamous carcinoma 10.4 CDKN2A TP53
48 anogenital venereal wart 10.3 CDKN2A TP53
49 sapho syndrome 10.3 MDM2 TP53
50 cervix uteri carcinoma in situ 10.3 CDKN2A TP53

Graphical network of the top 20 diseases related to Verrucous Carcinoma:



Diseases related to Verrucous Carcinoma

Symptoms & Phenotypes for Verrucous Carcinoma

GenomeRNAi Phenotypes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00293-A 8.8 KRT10 SLC2A1 TP53

MGI Mouse Phenotypes related to Verrucous Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.98 CCND1 CDKN2A LRIG1 MDM2 SLC2A1 TP53
2 homeostasis/metabolism MP:0005376 9.97 CCND1 CDKN2A LRIG1 MDM2 NOTCH4 SLC2A1
3 nervous system MP:0003631 9.86 CCND1 CDKN2A LRIG1 MDM2 NOTCH4 SLC2A1
4 digestive/alimentary MP:0005381 9.8 CCND1 CDKN2A LRIG1 MDM2 TP53
5 neoplasm MP:0002006 9.72 CCND1 CDKN2A LRIG1 MDM2 TP53
6 no phenotypic analysis MP:0003012 9.55 CDKN2A LRIG1 MDM2 SLC2A1 TP53
7 normal MP:0002873 9.43 CCND1 LRIG1 MDM2 MSN NOTCH4 TP53
8 skeleton MP:0005390 9.1 CCND1 CDKN2A LRIG1 MDM2 TP53 TYMP

Drugs & Therapeutics for Verrucous Carcinoma

Drugs for Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 210)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
3
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
5
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
6
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
7
Promethazine Approved, Investigational Phase 3 60-87-7 4927
8
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
9
Histamine Approved, Investigational Phase 3 51-45-6 774
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
14
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
15
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
16
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
17
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
18
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
19
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
20
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
21
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
22
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
24
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
25 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
26 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
27 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
28 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
29 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
36 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
38 Anti-Infective Agents Phase 2, Phase 3,Phase 1
39 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
40 Autonomic Agents Phase 3,Phase 2,Not Applicable
41 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Not Applicable
42
Histamine Phosphate Phase 3 51-74-1 65513
43 Antidepressive Agents Phase 3
44 Central Nervous System Depressants Phase 3
45 Psychotropic Drugs Phase 3
46 Antidepressive Agents, Tricyclic Phase 3
47 Histamine Antagonists Phase 3
48 Hypnotics and Sedatives Phase 3
49 Anesthetics, General Phase 3
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 141)
# Name Status NCT ID Phase Drugs
1 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
2 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
5 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
6 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
7 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
8 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
9 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
10 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
11 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
12 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
13 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
14 CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Withdrawn NCT01545687 Phase 3
15 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
16 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
17 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
18 Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Unknown status NCT00721513 Phase 2 cisplatin;docetaxel;fluorouracil
19 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
20 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
21 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
22 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
23 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
24 Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer Completed NCT02048020 Phase 2 paclitaxel;carboplatin
25 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
26 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
27 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
28 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
29 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
30 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
31 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
32 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
33 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
34 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
35 Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
36 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
37 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
38 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
39 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
40 Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery Completed NCT00738868 Phase 2
41 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
42 Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
43 Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride
44 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
45 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
46 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
47 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
48 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
49 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
50 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Completed NCT00833261 Phase 2 cetuximab;cisplatin

Search NIH Clinical Center for Verrucous Carcinoma

Cochrane evidence based reviews: carcinoma, verrucous

Genetic Tests for Verrucous Carcinoma

Anatomical Context for Verrucous Carcinoma

MalaCards organs/tissues related to Verrucous Carcinoma:

42
Skin, Cervix, Brain, Bone, Lymph Node, Kidney, Breast

Publications for Verrucous Carcinoma

Articles related to Verrucous Carcinoma:

(show top 50) (show all 659)
# Title Authors Year
1
Verrucous carcinoma: An unexpected finding arising from a burn scar. ( 30809566 )
2019
2
Downregulation of Notch4 - a prognostic marker in distinguishing oral verrucous carcinoma from oral squamous cell carcinoma. ( 29162408 )
2019
3
Lichenoid Characteristics in Premalignant Verrucous Lesions and Verrucous Carcinoma of the Oral Cavity. ( 30671763 )
2019
4
A first case of primary gastric verrucous carcinoma with isolated squamous epithelium in the stomach. ( 30761414 )
2019
5
Verrucous carcinoma on the foot arising in a chronic neuropathic ulcer of leprosy. ( 30841011 )
2019
6
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications. ( 30111295 )
2018
7
BCL-X expression in oral cancer: Comparison between oral squamous cell carcinoma and verrucous carcinoma. ( 29652014 )
2018
8
Verrucous carcinoma of the esophagus: A rare entity with a difficult diagnosis. ( 29452967 )
2018
9
Two Cases of Verrucous Carcinoma: Revisiting the Definition. ( 29540646 )
2018
10
A Case of Oral Florid Papillomatosis (Verrucous Carcinoma) With Lack of Evidence for Human Papillomavirus Involvement. ( 29697424 )
2018
11
Verrucous carcinoma of the esophagus-remains a diagnostic enigma. ( 29748561 )
2018
12
Mistaken Diabetic Ulcers: A Case of Bilateral Foot Verrucous Carcinoma. ( 29796321 )
2018
13
Corrigendum to "Mistaken Diabetic Ulcers: A Case of Bilateral Foot Verrucous Carcinoma". ( 29849220 )
2018
14
Recalcitrant lip verrucous carcinoma successfully treated with acitretin after carbon dioxide laser ablation. ( 29998178 )
2018
15
Verrucous Carcinoma Arising in Association With Giant Condyloma. ( 30185090 )
2018
16
Treatment of verrucous carcinoma in penis with topical aminolevulinic acid photodynamic therapy: An effective and safe treatment method. ( 30205190 )
2018
17
Verrucous carcinoma arising from a previous cystic lesion: a case report. ( 30397593 )
2018
18
Human papillomavirus infection is not involved in esophageal verrucous carcinoma. ( 30423307 )
2018
19
Anogenital Verrucous Carcinoma-A case report. ( 30508696 )
2018
20
Cutaneous Verrucous Carcinoma Superimposed on Chronically Inflamed Ileostomy Site Skin: A Case Report. ( 30697301 )
2018
21
A clitoral verrucous carcinoma in an area of lichen planus has aggressive features. ( 28061900 )
2017
22
Comorbidity between HTLV-1-associated adult T-cell lymphoma/leukemia and verrucous carcinoma: a case report. ( 28559645 )
2017
23
A population-based analysis of verrucous carcinoma of the oral cavity. ( 28850720 )
2017
24
Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity. ( 28150306 )
2017
25
Research on miRNA-195 and target gene CDK6 in oral verrucous carcinoma. ( 28621315 )
2017
26
Local Excision for the Treatment of Penile Verrucous Carcinoma. ( 28417078 )
2017
27
Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review. ( 27924463 )
2017
28
Human Papilloma Virus-Associated Lips Verrucous Carcinoma in HIV-Infected Male. ( 28565927 )
2017
29
Verrucous carcinoma of foot at an unusual site: Lessons to be learnt. ( 28702408 )
2017
30
Epidemiology and survival outcomes of sinonasal verrucous carcinoma in the United States. ( 28865078 )
2017
31
Rare "Inverted" Verrucous Carcinoma (Carcinoma Cuniculatum) of the Sacrogluteal Region: Case Report and Literature Review. ( 28381141 )
2017
32
Verrucous carcinoma of the oesophagus. ( 28116819 )
2017
33
Good Prognosis Went Badly: Fulminant Evolution of a 29-Year-Old Patient with Verrucous Carcinoma of the Cervix. ( 28498727 )
2017
34
Syringocystadenoma Papilliferum in Coexistence With Verrucous Carcinoma on the Face. ( 29112527 )
2017
35
Verrucous carcinoma of the buccal mucosa with extension to the cheek. ( 28319631 )
2017
36
A Giant Cutaneous Horn Projecting from Verrucous Carcinoma of Buccal Mucosa: A Rare Case Report. ( 28511519 )
2017
37
Verrucous carcinoma of the vulva: diagnosis and treatment. ( 28538888 )
2017
38
Malignant Transformation of a Site of Prior Diabetic Foot Ulceration to Verrucous Carcinoma: A Case Report. ( 29324428 )
2017
39
Oral Verrucous Carcinoma: Ten Year Experience from a Tertiary Care Hospital in India. ( 29333011 )
2017
40
Antioxidant enzymes in oral verrucous carcinoma. ( 27245640 )
2016
41
Investigation of the association between miRa89181b, Bcla892 and LRIG1 in oral verrucous carcinoma. ( 27509922 )
2016
42
The Akt/mTOR pathway is activated in verrucous carcinoma of the oral cavity. ( 26775690 )
2016
43
Reconstruction of the Auricular Defect After Excision of Verrucous Carcinoma. ( 26674896 )
2016
44
Pyoderma Vegetans Misdiagnosed as Verrucous Carcinoma. ( 26825160 )
2016
45
Subungual Verrucous Carcinoma of the Right Little Finger with Underlying Bony Invasion. ( 27746655 )
2016
46
Intraosseous verrucous carcinoma arising from an orthokeratinized odontogenic keratocyst: A report of a rarest entity. ( 27630514 )
2016
47
Oral verrucous hyperplasia versus oral verrucous carcinoma: A clinicopathologic dilemma revisited using p53 as immunohistochemical marker. ( 27721598 )
2016
48
Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature. ( 27307433 )
2016
49
Verrucous carcinoma arising in a port wine stain. ( 26809361 )
2016
50
Verrucous Carcinoma of the Esophagus. ( 27803424 )
2016

Variations for Verrucous Carcinoma

Expression for Verrucous Carcinoma

Search GEO for disease gene expression data for Verrucous Carcinoma.

Pathways for Verrucous Carcinoma

Pathways related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 CCND1 CDKN2A MDM2 MSN NOTCH4 TP53
2
Show member pathways
12.82 CCND1 MDM2 NOTCH4 TP53
3
Show member pathways
12.71 CCND1 CDKN2A MDM2 TP53
4
Show member pathways
12.61 CCND1 CDKN2A NOTCH4 TP53
5
Show member pathways
12.5 CCND1 CDKN2A MDM2 NOTCH4 TP53
6
Show member pathways
12.47 CCND1 MDM2 SLC2A1 TP53
7 12.46 CCND1 CDKN2A MDM2 NOTCH4 SLC2A1 TP53
8
Show member pathways
12.45 CCND1 CDKN2A MDM2 TP53
9 12.39 CCND1 CDKN2A MDM2 TP53
10
Show member pathways
12.25 CCND1 CDKN2A MDM2 TP53
11
Show member pathways
12.24 CCND1 MDM2 TP53
12 12.24 CCND1 CDKN2A MDM2 TP53
13 12.23 CCND1 CDKN2A SLC2A1 TP53
14
Show member pathways
12.21 CCND1 CDKN2A TP53
15 12.2 CCND1 CDKN2A MDM2 NOTCH4 TP53
16 12.15 CCND1 MDM2 MSN TP53
17 12.14 CCND1 CDKN2A MDM2 TP53
18
Show member pathways
12.11 CCND1 MDM2 TP53
19 12.01 CCND1 MDM2 TP53
20 12 CCND1 MDM2 TP53
21 12 CCND1 CDKN2A MDM2 TP53
22 11.92 CDKN2A MDM2 TP53
23
Show member pathways
11.91 CCND1 NOTCH4 TP53
24 11.83 CDKN2A MDM2 TP53
25 11.82 CCND1 CDKN2A MDM2 TP53
26 11.74 CCND1 MDM2 TP53
27 11.71 CCND1 CDKN2A MDM2 TP53
28 11.64 CDKN2A MDM2 TP53
29
Show member pathways
11.64 CDKN2A MDM2 TP53
30 11.56 CDKN2A MDM2 TP53
31 11.48 CCND1 MDM2 TP53
32 11.44 CCND1 CDKN2A TP53
33 11.42 CCND1 MDM2 NOTCH4 SLC2A1 TP53
34 11.34 CCND1 MDM2 TP53
35 11.25 SLC2A1 TP53
36 11.19 CDKN2A MDM2 SLC2A1 TP53
37 11.18 CCND1 TP53
38 11.16 MDM2 TP53
39 11.16 CDKN2A MDM2 TP53
40 10.95 CDKN2A MDM2 TP53
41
Show member pathways
10.92 CDKN2A MDM2 TP53
42 10.88 CCND1 CDKN2A MDM2 TP53 TYMP

GO Terms for Verrucous Carcinoma

Cellular components related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.28 CCND1 CDKN2A KRT10 MDM2 MSN NOTCH4

Biological processes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.71 CDKN2A MDM2 MSN TP53
2 protein sumoylation GO:0016925 9.54 CDKN2A MDM2
3 protein-containing complex assembly GO:0065003 9.54 MDM2 SLC2A1 TP53
4 response to antibiotic GO:0046677 9.52 MDM2 TP53
5 response to steroid hormone GO:0048545 9.51 CCND1 MDM2
6 cellular response to gamma radiation GO:0071480 9.49 MDM2 TP53
7 negative regulation of cell cycle arrest GO:0071157 9.48 CCND1 MDM2
8 positive regulation of protein export from nucleus GO:0046827 9.46 MDM2 TP53
9 response to iron ion GO:0010039 9.43 CCND1 MDM2
10 replicative senescence GO:0090399 9.32 CDKN2A TP53
11 response to magnesium ion GO:0032026 9.26 CCND1 MDM2
12 amyloid fibril formation GO:1990000 9.16 CDKN2A MDM2
13 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
14 cellular response to actinomycin D GO:0072717 8.62 MDM2 TP53

Molecular functions related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.46 CCND1 CDKN2A MSN TP53
2 SUMO transferase activity GO:0019789 9.26 CDKN2A MDM2
3 enzyme binding GO:0019899 9.26 CCND1 MDM2 MSN TP53
4 disordered domain specific binding GO:0097718 8.8 CDKN2A MDM2 TP53

Sources for Verrucous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....